MGMT and neoplasm: For the patients whose tumours underwent molecular testing, there was no difference in the proportion of tumours with methylated MGMT (17% vs 26%, p = 0.096), EGFR amplification (42% vs 37%, p = 0.416), or Chr 7+/10- (53% vs 37%, p = 0.068).